Global Information
회사소개 | 문의 | 비교리스트

알레르기성 결막염 : 파이프라인 리뷰

Allergic Conjunctivitis (Ophthalmology) - Drugs In Development, 2021

리서치사 Global Markets Direct
발행일 2021년 08월 상품코드 192452
페이지 정보 영문 132 Pages 배송안내
가격
US $ 2,000 ₩ 2,841,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,682,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 8,523,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


알레르기성 결막염 : 파이프라인 리뷰 Allergic Conjunctivitis (Ophthalmology) - Drugs In Development, 2021
발행일 : 2021년 08월 페이지 정보 : 영문 132 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

알레르기성 결막염은 눈꺼풀 및 백안(결막)을 덮는 조직의 투명층이 꽃가루, 비듬, 곰팡이 및 기타 알레르기 원인 물질에 의해 붓거나 염증 발생시 발병합니다. 증상에는 극심한 가려움, 안검 부종, 결막을 덮고 있는 투명 세포층의 혈관 확대(확장) 및 끈끈한 눈곱이 포함됩니다. 치료에는 항히스타민제 또는 항염증제 요법이 이용됩니다.

세계의 알레르기성 결막염 치료제 파이프라인 제품에 대해 분석했으며, 현재 개발 파이프라인의 상황 및 최신 동향, 후기 단계 및 중지된 프로젝트의 정보, 주요 기업 및 개발중인 제품의 리뷰 등을 정리하여 전해드립니다.

서론

  • 조사 범위

알레르기성 결막염 - 개요

알레르기성 결막염 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 기업에서 개발중인 제품

알레르기성 결막염 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

알레르기성 결막염 치료제 개발에 참여하고 있는 기업

약제 개요

알레르기성 결막염 - 휴지중인 프로젝트

알레르기성 결막염 - 개발이 중지된 제품

알레르기성 결막염 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

List of Tables

List of Tables

  • Number of Products under Development for Allergic Conjunctivitis, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Allergic Conjunctivitis - Pipeline by AbbVie Inc, 2021
  • Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, 2021
  • Allergic Conjunctivitis - Pipeline by Ajanta Pharma Ltd, 2021
  • Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, 2021
  • Allergic Conjunctivitis - Pipeline by Alexion Pharmaceuticals Inc, 2021
  • Allergic Conjunctivitis - Pipeline by ALK-Abello AS, 2021
  • Allergic Conjunctivitis - Pipeline by Allakos Inc, 2021
  • Allergic Conjunctivitis - Pipeline by Clevexel Pharma SA, 2021
  • Allergic Conjunctivitis - Pipeline by Faes Farma SA, 2021
  • Allergic Conjunctivitis - Pipeline by IACTA Pharmaceuticals Inc, 2021
  • Allergic Conjunctivitis - Pipeline by Intas Pharmaceuticals Ltd, 2021
  • Allergic Conjunctivitis - Pipeline by JW Pharmaceutical Corp, 2021
  • Allergic Conjunctivitis - Pipeline by Kissei Pharmaceutical Co Ltd, 2021
  • Allergic Conjunctivitis - Pipeline by Nanomerics Ltd, 2021
  • Allergic Conjunctivitis - Pipeline by NicOx SA, 2021
  • Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, 2021
  • Allergic Conjunctivitis - Pipeline by OKYO Pharma Ltd, 2021
  • Allergic Conjunctivitis - Pipeline by Oyster Point Pharma Inc, 2021
  • Allergic Conjunctivitis - Pipeline by Quark Pharmaceuticals Inc, 2021
  • Allergic Conjunctivitis - Dormant Projects, 2021
  • Allergic Conjunctivitis - Dormant Projects, 2021 (Contd..1)
  • Allergic Conjunctivitis - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Allergic Conjunctivitis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Drugs In Development, 2021, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 2, 12 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Allergic Conjunctivitis - Overview
  • Allergic Conjunctivitis - Therapeutics Development
  • Allergic Conjunctivitis - Therapeutics Assessment
  • Allergic Conjunctivitis - Companies Involved in Therapeutics Development
  • Allergic Conjunctivitis - Drug Profiles
  • Allergic Conjunctivitis - Dormant Projects
  • Allergic Conjunctivitis - Discontinued Products
  • Allergic Conjunctivitis - Product Development Milestonesh
  • Appendix
Back to Top
전화 문의
F A Q